Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTH NASDAQ:ELGX NASDAQ:IDXG NASDAQ:SNWV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$763K4.024,068 shs455 shsELGXEndologix$0.07$0.03$0.22▼$7.10$1.41M0.731.28 million shs85,372 shsIDXGInterpace Biosciences$0.93-0.2%$8.06$2.57▼$10.42$4.10M0.766,816 shs1,819 shsSNWVSanuwave Health$33.93-3.1%$37.23$10.00▼$46.58$299.88M1.33125,229 shs239,793 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%0.00%-99.30%ELGXEndologix0.00%0.00%0.00%0.00%0.00%IDXGInterpace Biosciences-0.83%+0.26%+2.46%+8.41%-53.84%SNWVSanuwave Health-3.06%+5.18%-4.23%-13.53%+3,392,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$763K4.024,068 shs455 shsELGXEndologix$0.07$0.03$0.22▼$7.10$1.41M0.731.28 million shs85,372 shsIDXGInterpace Biosciences$0.93-0.2%$8.06$2.57▼$10.42$4.10M0.766,816 shs1,819 shsSNWVSanuwave Health$33.93-3.1%$37.23$10.00▼$46.58$299.88M1.33125,229 shs239,793 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%0.00%-99.30%ELGXEndologix0.00%0.00%0.00%0.00%0.00%IDXGInterpace Biosciences-0.83%+0.26%+2.46%+8.41%-53.84%SNWVSanuwave Health-3.06%+5.18%-4.23%-13.53%+3,392,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/AELGXEndologix 0.00N/AN/AN/AIDXGInterpace Biosciences 0.00N/AN/AN/ASNWVSanuwave Health 2.75Moderate Buy$54.0059.15% UpsideCurrent Analyst Ratings BreakdownLatest ELGX, IDXG, SNWV, and ARTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025SNWVSanuwave HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$53.009/27/2025SNWVSanuwave HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/3/2025SNWVSanuwave HealthNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025SNWVSanuwave HealthNorthland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$55.008/22/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $55.007/29/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$49.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.00N/AN/A($2.43) per share0.00ELGXEndologix$143.37M0.01N/AN/A$3.56 per share0.02IDXGInterpace Biosciences$40.21M0.10$0.47 per share1.99($14.16) per share-0.07SNWVSanuwave Health$39.19M7.42N/AN/A($1.49) per share-22.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%N/AELGXEndologix-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/AIDXGInterpace Biosciences$800KN/A0.00∞N/A10.39%-8.09%37.14%N/ASNWVSanuwave Health-$31.37M-$8.25N/A∞N/A-97.03%N/A-135.15%N/ALatest ELGX, IDXG, SNWV, and ARTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025SNWVSanuwave Health-$0.09$0.01+$0.10$0.01$10.14 million$10.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/AELGXEndologixN/AN/AN/AN/AN/AIDXGInterpace BiosciencesN/AN/AN/AN/AN/ASNWVSanuwave HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01ELGXEndologix0.290.390.28IDXGInterpace BiosciencesN/A0.590.59SNWVSanuwave HealthN/A0.430.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%ELGXEndologix51.61%IDXGInterpace Biosciences5.73%SNWVSanuwave Health42.53%Insider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%ELGXEndologix1.30%IDXGInterpace Biosciences5.50%SNWVSanuwave Health14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableELGXEndologix52819.17 millionN/AOptionableIDXGInterpace Biosciences1524.41 million4.17 millionNot OptionableSNWVSanuwave Health408.57 million7.29 millionN/AELGX, IDXG, SNWV, and ARTH HeadlinesRecent News About These Companies25,050 Shares in Sanuwave Health Inc. $SNWV Bought by Evernest Financial Advisors LLCOctober 16 at 6:37 AM | marketbeat.comQ4 EPS Estimates for Sanuwave Health Cut by Northland CapmkOctober 11, 2025 | americanbankingnews.comFY2025 EPS Forecast for Sanuwave Health Decreased by AnalystOctober 11, 2025 | americanbankingnews.comSanuwave Health (NASDAQ:SNWV) Lowered to "Hold" Rating by Wall Street ZenOctober 11, 2025 | marketbeat.comQ4 EPS Estimates for Sanuwave Health Reduced by AnalystOctober 10, 2025 | marketbeat.comRoth Capital Reduces Earnings Estimates for Sanuwave HealthOctober 10, 2025 | marketbeat.comQ3 EPS Estimates for Sanuwave Health Lowered by Roth CapitalOctober 10, 2025 | americanbankingnews.comQ3 EPS Estimates for Sanuwave Health Cut by Northland CapmkOctober 10, 2025 | americanbankingnews.comSanuwave Health's (SNWV) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 9, 2025 | marketbeat.comNorthland Capmk Predicts Weaker Earnings for Sanuwave HealthOctober 8, 2025 | marketbeat.comRoth Capital Forecasts Reduced Earnings for Sanuwave HealthOctober 8, 2025 | marketbeat.comSanuwave Health (SNWV) Surges 9.1%: Is This an Indication of Further Gains?October 7, 2025 | zacks.comSANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call TranscriptOctober 6, 2025 | seekingalpha.comSanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)October 6, 2025 | globenewswire.comSanuwave Health (NASDAQ:SNWV) Upgraded at Wall Street ZenOctober 3, 2025 | marketbeat.comSANUWAVE Health Insider Ups Holding By 124% During YearOctober 2, 2025 | finance.yahoo.com3 Lesser-Known Healthcare Names With Major Upside in Store (SNWV)...October 2, 2025 | marketbeat.comFY2025 EPS Estimates for Sanuwave Health Raised by AnalystOctober 1, 2025 | marketbeat.comGoldman Sachs Group Inc. Makes New Investment in Sanuwave Health Inc. $SNWVSeptember 28, 2025 | marketbeat.comSanuwave Announces Strategic Debt Refinancing with New Credit FacilitySeptember 26, 2025 | globenewswire.comSanuwave Health (NASDAQ:SNWV) Cut to Hold at Wall Street ZenSeptember 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELGX, IDXG, SNWV, and ARTH Company DescriptionsArch Therapeutics OTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Endologix NASDAQ:ELGXEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.Interpace Biosciences NASDAQ:IDXGInterpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.Sanuwave Health NASDAQ:SNWV$33.93 -1.07 (-3.06%) As of 10/17/2025 04:00 PM EasternSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
